Advaxis CEO: Institutional Interest in Immunotherapy Driving Stock

Advaxis has seen its shares surge higher in the past month due to increased institutional interest and an optimistic response from investors to its 2015 outlook, said the company's CEO Dan O'Connor. O'Connor added that Boston's Adage Capital and T. Rowe Price are the large players that have taken significant positions in Advaxis. He said Advaxis has partnerships with Merck and MedImmune to explore their immunotherapy technology in combination with other agents and is seeking additional partners. O'Connor said he expects to start a Phase 3 trial for its cervical cancer therapy in the first half of 2015. Finally, he said the company has raised enough money to operate until July 2016 without a significant change in its operations.